Serrano Isa, Mil-Homens Dalila, Pires Rita F, Bonifácio Vasco D B, Guerreiro Joana F, Cunha Eva, Costa Sofia S, Tavares Luís, Oliveira Manuela
CIISA-Center for Interdisciplinary Research in Animal Health, Faculty of Veterinary Medicine, University of Lisbon, Av. Universidade Técnica, 1300-477 Lisbon, Portugal.
Associate Laboratory for Animal and Veterinary Sciences (AL4AnimalS), Faculty of Veterinary Medicine, University of Lisbon, Av. Universidade Técnica, 1300-477 Lisbon, Portugal.
Antibiotics (Basel). 2025 Apr 28;14(5):444. doi: 10.3390/antibiotics14050444.
BACKGROUND/OBJECTIVES: Diabetic foot infections (DFIs) are commonly associated with frequent hospitalizations, limb amputations, and premature death due to the profile of the bacteria infecting foot ulcers. DFIs are generally colonized by a polymicrobial net of bacteria that grows in biofilms, developing an increased antimicrobial resistance to multiple antibiotics. DFI treatment is a hurdle, and the need to develop new therapies that do not promote resistance is urgent. Therefore, the antibacterial efficacy of Nisin Z (antimicrobial peptide), a core-shell polycationic polyurea pharmadendrimer (PUREOEI) (antimicrobial polymer), and amlodipine (antihypertensive drug) was evaluated against and isolated from a DFI and previously characterized.
The antibacterial activity was analyzed in vitro by determining the minimal inhibitory concentration (MIC) and in vivo in a model by assessing the larvae survival and health index.
The results indicate that Nisin Z exhibited antibacterial activity against in vivo, allowing larvae full survival, and no antibacterial activity against . Nisin Z may have reduced the antibacterial effectiveness of both PUREOEI and amlodipine. PUREOEI significantly increased the survival of the larvae infected with , while amlodipine showed no activity against both bacteria in vivo.
These findings suggest that both Nisin Z and PUREOEI could potentially be used individually as adjunct treatments for mild DFIs. However, further studies are needed to confirm these findings and assess the potential toxicity and efficacy of PUREOEI in more complex models.
背景/目的:糖尿病足感染(DFIs)通常与频繁住院、肢体截肢以及因感染足部溃疡的细菌特性导致的过早死亡相关。DFIs一般被生长在生物膜中的多种细菌定植,对多种抗生素产生越来越强的抗药性。DFI治疗是一个难题,迫切需要开发不会促进抗药性的新疗法。因此,评估了乳酸链球菌素Z(抗菌肽)、核壳聚阳离子聚脲药物树枝状大分子(PUREOEI)(抗菌聚合物)和氨氯地平(抗高血压药物)对从DFI中分离并先前已鉴定的[具体细菌名称1]和[具体细菌名称2]的抗菌效果。
通过测定最低抑菌浓度(MIC)在体外分析抗菌活性,并在[具体动物模型名称]模型中通过评估幼虫存活率和健康指数在体内分析抗菌活性。
结果表明,乳酸链球菌素Z在体内对[具体细菌名称1]表现出抗菌活性,使幼虫完全存活,而对[具体细菌名称2]无抗菌活性。乳酸链球菌素Z可能降低了PUREOEI和氨氯地平两者的抗菌效果。PUREOEI显著提高了感染[具体细菌名称2]的幼虫的存活率,而氨氯地平在体内对两种细菌均无活性。
这些发现表明,乳酸链球菌素Z和PUREOEI都有可能单独用作轻度DFIs的辅助治疗。然而,需要进一步研究来证实这些发现,并评估PUREOEI在更复杂模型中的潜在毒性和疗效。